---
title: "Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293607988.md"
description: "Nuvectis partner Haisco received China NMPA marketing approval for ciprocopan (NXP100) to treat treatment-naive paroxysmal nocturnal hemoglobinuria patients. Ciprocopan is the first once-daily oral complement Factor B inhibitor to achieve global approval. A separate application for previously treated PNH patients is currently under NMPA review."
datetime: "2026-07-23T11:32:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293607988.md)
  - [en](https://longbridge.com/en/news/293607988.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293607988.md)
generator: "portal-rs"
---

# Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patients

-   Nuvectis partner Haisco secured China NMPA marketing clearance for ciprocopan (NXP100) in treatment-naive paroxysmal nocturnal hemoglobinuria patients. \* Ciprocopan is the first once-daily oral complement Factor B inhibitor to win global approval. \* A separate China filing for PNH patients previously treated with anti-C5 therapies remains under NMPA review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230730PRIMZONEFULLFEED9767018) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)
- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)

## Related News & Research

- [Nuvectis Pharma to present at H.C. Wainwright annual investment conference](https://longbridge.com/en/news/297909736.md)
- [China's Haisco Gets China’s Nod for Rare Blood Disorder Drug](https://longbridge.com/en/news/293607538.md)
- [Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co](https://longbridge.com/en/news/297931335.md)
- [NorthCore Life’s LotosPFA wins China NMPA approval for nano pulsed-field ablation system](https://longbridge.com/en/news/297260650.md)
- [Ideaship invests in Hemex Health](https://longbridge.com/en/news/297682058.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**